Lyell Wealth Management’s Aimmune Therapeutics AIMT Stock Holding History

Lyell Wealth Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,000	Closed	-$207K	–	163
2020 Q3	$207K	Buy	+6,000	New	+$128K	0.04%	131

Lyell Wealth Management's AIMT Position: Q4 2020 in Review

Lyell Wealth Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 6,000 shares — an estimated $207K sold.

Lyell Wealth Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $207K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Lyell Wealth Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Lyell Wealth Management sold 6,000 Aimmune Therapeutics shares in Q4 2020, an estimated $207K.
Lyell Wealth Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Lyell Wealth Management's Aimmune Therapeutics position peaked at $207K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Lyell Wealth Management's 13F filing for Q4 2020, filed 4 Feb 2021.